Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

Similar articles for PubMed (Select 23389842)

1.

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Mov Disord. 2013 Jul;28(8):1088-96. doi: 10.1002/mds.25366. Epub 2013 Feb 6.

PMID:
23389842
2.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

3.

5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.

Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.

Neurobiol Dis. 2013 Dec;60:108-14. doi: 10.1016/j.nbd.2013.08.014. Epub 2013 Sep 1.

PMID:
24004632
4.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129
5.

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.

Shin E, Garcia J, Winkler C, Björklund A, Carta M.

Neurobiol Dis. 2012 Sep;47(3):393-406. doi: 10.1016/j.nbd.2012.03.038. Epub 2012 Apr 12.

PMID:
22579773
6.

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.

Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.

7.

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.

Kobylecki C, Hill MP, Crossman AR, Ravenscroft P.

Mov Disord. 2011 Nov;26(13):2354-63. doi: 10.1002/mds.23867. Epub 2011 Sep 23.

PMID:
21953539
8.

Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.

J Neural Transm. 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21.

PMID:
21253782
9.

Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.

Ko WK, Li Q, Bezard E.

Neurosci Lett. 2014 Apr 30;566:72-6. doi: 10.1016/j.neulet.2014.02.027. Epub 2014 Feb 23.

PMID:
24572591
10.

The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.

Thornton E, Hassall MM, Corrigan F, Vink R.

Parkinsonism Relat Disord. 2014 May;20(5):508-13. doi: 10.1016/j.parkreldis.2014.02.008. Epub 2014 Feb 20.

PMID:
24637127
11.

Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

Zhang H, Ma L, Wang F, Chen J, Zhen X.

Neuropharmacology. 2007 Jul;53(1):125-33. Epub 2007 Apr 29.

PMID:
17553535
12.

Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.

Shin E, Rogers JT, Devoto P, Björklund A, Carta M.

Exp Neurol. 2014 Jul;257:25-38. doi: 10.1016/j.expneurol.2014.04.011. Epub 2014 Apr 18.

PMID:
24747357
13.

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

Carta M, Carlsson T, Kirik D, Björklund A.

Brain. 2007 Jul;130(Pt 7):1819-33. Epub 2007 Apr 23.

14.

Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.

Nahimi A, Høltzermann M, Landau AM, Simonsen M, Jakobsen S, Alstrup AK, Vang K, Møller A, Wegener G, Gjedde A, Doudet DJ.

J Neurochem. 2012 Mar;120(5):806-17. doi: 10.1111/j.1471-4159.2011.07598.x. Epub 2012 Jan 23.

PMID:
22117574
15.

Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.

Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, Eissa S, Eskow Jaunarajs KL.

Eur J Neurosci. 2012 Sep;36(6):2839-48. doi: 10.1111/j.1460-9568.2012.08202.x. Epub 2012 Jul 5.

16.

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

Maratos EC, Jackson MJ, Pearce RK, Cannizzaro C, Jenner P.

Exp Neurol. 2003 Jan;179(1):90-102.

PMID:
12504871
17.

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

Eskow KL, Gupta V, Alam S, Park JY, Bishop C.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14. Epub 2007 May 13.

PMID:
17553556
18.

An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.

Spinnewyn B, Charnet C, Cornet S, Roubert V, Chabrier PE, Auguet M.

Fundam Clin Pharmacol. 2011 Oct;25(5):608-18. doi: 10.1111/j.1472-8206.2010.00883.x. Epub 2010 Nov 16.

PMID:
21077938
19.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
20.

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD.

J Neurosci Res. 2009 May 15;87(7):1645-58. doi: 10.1002/jnr.21978.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk